Literature DB >> 15542935

Plasma leptin concentration in tamoxifen-treated ovariectomized rats.

Yasuo Hozumi1, Yoji Hakamata, Hideo Nagai.   

Abstract

UNLABELLED: Leptin, the ob gene product, has an important role in the regulation of body weight. Although tamoxifen, a nonsteroidal antiestrogenic agent, is known to have estrogenic effects on fat metabolism, its influence on adipose tissue remains unknown. In the present study, the effect of tamoxifen on the concentration of leptin was investigated in ovariectomized rats treated with tamoxifen or vehicle. The dosage of tamoxifen was extrapolated from the human dosage. Food intake, adipose tissue weight, and plasma insulin were assessed at the end of the experiment.
RESULTS: Tamoxifen-treated rats showed a significant reduction of body weight gain, food intake, adipose tissue weight and leptin concentration (p < 0.001). The plasma insulin level was significantly higher after tamoxifen treatment (p = 0.01) in tamoxifen-treated rats than in control rats. We concluded that tamoxifen reduces food intake in the acute phase and a reduction of adipose tissue gain may result in reduced levels of plasma leptin in ovariectomized rats. Furthermore, rats treated with tamoxifen may be resistant to insulin action. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542935     DOI: 10.1159/000082111

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  2 in total

1.  Influence of gender on tamoxifen-induced biochemical changes in serum of rats.

Authors:  Faried Abdel-Kader El-Sayed Hemieda
Journal:  Mol Cell Biochem       Date:  2007-02-06       Impact factor: 3.842

2.  Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.

Authors:  Jesús Loureiro; Pilar Sandoval; Gloria del Peso; Guadalupe Gónzalez-Mateo; Vanessa Fernández-Millara; Beatríz Santamaria; Maria Auxiliadora Bajo; José Antonio Sánchez-Tomero; Gonzalo Guerra-Azcona; Rafael Selgas; Manuel López-Cabrera; Abelardo I Aguilera
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.